A DARPA-Funded Implantable Biochip To Detect COVID-19 Could Hit Markets By 2021
Is Pfizer Stock a Buy Right Now? This Is What You Need to Know
Wells Fargo: These 2 Stocks Could Deliver Triple-Digit Wins
Roche says a second trial of Actemra revives hopes for IL-6. What now?
Roche’s Actemra cuts chances of COVID-19 ventilator use in phase 3 trial
Pfizer vaccine trial bets on early win against coronavirus, documents show
Silicon Valley startup Visby’s portable Covid-19 test gets FDA approval
Biden Joins FDA Critics, Seeks Independent Vaccine Review
CVS Health Gets A Buy Rating From Piper Sandler
3 "Strong Buy" Healthcare Stocks With Major Catalysts Approaching
Eli Lilly Strikes Deal With Amgen To Manufacture Covid-19 Antibody Therapies
Moderna Stock Rises 3% On Vertex Deal
BioNTech Buys German Site From Novartis To Boost Covid-19 Vaccine Supply
Covid-19 roundup: Trump questions Redfield after hearing remarks; Oxford suggests side effect not caused by vaccine
Sorrento Pops 28% On FDA Nod To Kick Off Covid-19 Antibody Trial
Illumina Eyes Grail Acquisition For Over $8B – Report
Gilead Sciences: Don’t Underestimate This Pharma Giant’s Growth Potential, Says Analyst
Vaxart Can Still Be a Major Force in the COVID-19 Vaccine Landscape, Says Analyst
Morgan Stanley Bets on These 3 Stocks; Sees Over 40% Upside
Concerns Mount – FDA May Approve Deadly Vaccine
Bill Gates embroiled in controversy over coronavirus vaccine safety
NIH Raises Concerns About Potential Safety Issues Associated with AstraZeneca Vaccine
Former FDA Executive on COVID-19 and Convalescent Plasma
News briefing: Top FDA official exits; Sun Genomics closes $9.25M Series A
Abbott Starts Shipping 15-Minute Covid-19 Test After FDA Emergency Use Nod
Why AstraZeneca and others racing to make a COVID-19 vaccine should be more open about the process
Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-19 therapy
Covid-19 Vaccine Makers’ Pledge May Not Quell Uprising
Penumbra Inc.’s Catheter Fail: Broken Tips and Lost Lives
NIH ‘very concerned’ about serious side effect in AstraZeneca's PhIII Covid-19 trial